Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus observation after complete resection of Merkel cell carcinoma
2013-000043-78Phase 2Completed
- Sponsor
- University of Duisburg-Essen
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Merkel cell carcinoma (MCC) comparing Adjuvant nivolumab with Observation (2 arms). Primary endpoint: Disease-free survival rate. Started Jan 2014; status: completed.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2013-000043-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000043-78.